Phase 2b Enrollments for Island's Dengue Fever Trial Completed
Island Pharmaceuticals announced that its phase 2 study is split into two cohorts: a phase 2a prophylactic (preventative) cohort and a phase 2b therapeutic (treatment) cohort. In the phase 2a cohort, participants were pre-treated with ISLA-101 before being exposed to a weakened or attenuated strain of the dengue virus. The goal is to determine whether ISLA-101 can prevent or reduce infection when administered prior to exposure. In the phase 2b cohort, the study focuses on evaluating whether ISLA-101 can lower virus levels and alleviate symptoms in individuals already infected with the dengue challenge virus. Through these two cohorts, Island aims to assess the potential of ISLA-101 as both a prophylactic and therapeutic option for dengue infection.
Phase 2b Enrollments for Island's Dengue Fever Trial Completed